Overall, we have seen an increase in the use of dabigatran after the availability of idarucizumab. We should recognize, however, that we know that all 4 DOACs (direct oral anticoagulants) are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback